Cervical Cancer Research Today is a free monthly online journal that collates and summarizes the latest research about Cervical Cancer, including details on symptoms, vaccine, screening, treatment, human papilloma virus (hpv), information.

Volume 2 (2005), Issue 2 (February)

1. The effect of loop electrosurgical excision procedure on future pregnancy outcome.
   Obstet Gynecol, 105(2): 325-32. [Abstract] [Full-text]
2. HIV infection and invasive cervical cancers, treatment with radiation therapy: toxicity and outcome.
   Radiother Oncol, 74(1): 31-5. [Abstract] [Full-text]
3. In vivo cervical cancer growth inhibition by genetically engineered cytotoxic T cells.
   Cancer Immunol Immunother, 54(1): 51-60. [Abstract] [Full-text]
4. Current cervical neoplasia screening practices of obstetrician/gynecologists in the US.
   Am J Obstet Gynecol, 192(2): 414-21. [Abstract] [Full-text]
5. Population characteristics in cervical cancer trials: search for external validity.
   Am J Obstet Gynecol, 192(2): 407-13. [Abstract] [Full-text]
6. Screening for cervical cancer: will women accept less?
   Am J Med, 118(2): 151-8. [Abstract] [Full-text]
7. Immunophenotypic alteration of the stromal component in minimal deviation adenocarcinoma ('adenoma malignum') and endocervical glandular hyperplasia: a study using oestrogen receptor and alpha-smooth muscle actin double immunostaining.
   Histopathology, 46(2): 130-6. [Abstract] [Full-text]
8. Loss of net as repressor leads to constitutive increased c-fos transcription in cervical cancer cells.
   J Biol Chem, 280(5): 3286-94. [Abstract] [Full-text]
9. Expression of the proapoptotic protein Bid is an adverse prognostic factor for radiotherapy outcome in carcinoma of the cervix.
   Br J Cancer, 92(3): 449-58. [Abstract] [Full-text]
10. Making sense of information about HPV in cervical screening: a qualitative study.
    Br J Cancer, 92(2): 265-70. [Abstract] [Full-text]
11. The human papillomavirus E6 and E7 inducible oncogene, hWAPL, exhibits potential as a therapeutic target.
    Br J Cancer, 92(2): 290-3. [Abstract] [Full-text]
12. Correlation between the tumoral expression of beta3-integrin and outcome in cervical cancer patients who had undergone radiotherapy.
    Br J Cancer, 92(1): 41-6. [Abstract] [Full-text]
13. Human papillomavirus genotyping and p16INK4a expression in cervical intraepithelial neoplasia of adolescents.
    Mod Pathol, 18(2): 267-73. [Abstract] [Full-text]
14. Concomitant chemobrachyradiotherapy with ifosfamide and cisplatin followed by consolidation chemotherapy in locally advanced squamous cell carcinoma of the uterine cervix: results of a phase II study.
    Int J Radiat Oncol Biol Phys, 61(3): 824-9. [Abstract] [Full-text]
15. Pathologic response and toxicity assessment of chemoradiotherapy with cisplatin versus cisplatin plus gemcitabine in cervical cancer: a randomized Phase II study.
    Int J Radiat Oncol Biol Phys, 61(3): 817-23. [Abstract] [Full-text]
16. Müllerian papilloma of the cervix in a child with multiple renal cysts.
    Urology, 65(2): 388. [Abstract] [Full-text]
17. Cervical adenoid basal tumors comprised of adenoid basal epithelioma associated with various types of invasive carcinoma: clinicopathologic features, human papillomavirus DNA detection, and P16 expression.
    Hum Pathol, 36(1): 82-90. [Abstract] [Full-text]
18. IFN-gamma/IRF-1-induced p27kip1 down-regulates telomerase activity and human telomerase reverse transcriptase expression in human cervical cancer.
    FEBS Lett, 579(5): 1027-33. [Abstract] [Full-text]
19. Serum vascular endothelial growth factor (VEGF) and VEGF-C levels as tumor markers in patients with cervical carcinoma.
    Cancer, 103(4): 724-30. [Abstract] [Full-text]
20. Methylenetetrahydrofolate reductase (MTHFR) and susceptibility for (pre)neoplastic cervical disease.
    Hum Genet, 116(4): 247-54. [Abstract] [Full-text]
21. Cross-typic specificity and immunotherapeutic potential of a human HPV16 E7-specific CTL line.
    Int J Cancer, 114(4): 606-12. [Abstract] [Full-text]
22. Clinicopathological features influencing pelvic lymph node metastasis and vaginal and parametrial involvement in patients with carcinoma of the cervix.
    Gynecol Obstet Invest, 59(2): 92-6. [Abstract] [Full-text]
23. Human papillomavirus type 18 variants: histopathology and E6/E7 polymorphisms in three countries.
    Int J Cancer, 114(3): 422-5. [Abstract] [Full-text]
24. Detection of hypermethylated genes in women with and without cervical neoplasia.
    J Natl Cancer Inst, 97(4): 273-82. [Abstract] [Full-text]
25. Abdominal radical trachelectomy: a fertility-preserving option for women with early cervical cancer.
    BJOG, 112(3): 366-9. [Abstract] [Full-text]
26. Is radical hysterectomy for early stage cervical cancer an outdated operation?
    BJOG, 112(3): 363-5. [Abstract] [Full-text]
27. Estrogen contributes to the onset, persistence, and malignant progression of cervical cancer in a human papillomavirus-transgenic mouse model.
    Proc Natl Acad Sci U S A, 102(7): 2490-5. [Abstract] [Full-text]
28. TNF-alpha promoter polymorphisms and susceptibility to human papillomavirus 16-associated cervical cancer.
    J Infect Dis, 191(6): 969-76. [Abstract] [Full-text]
29. Plasmacytoid dendritic cells are present in cervical carcinoma and become activated by human papillomavirus type 16 virus-like particles.
    Gynecol Oncol, 96(3): 897-901. [Abstract] [Full-text]
30. Metastatic adenocarcinoma of the cervix in a delivery-induced traumatic lower vaginal tear.
    Gynecol Oncol, 96(3): 857-9. [Abstract] [Full-text]
31. Central pelvic recurrence 7 years after radical vaginal trachelectomy.
    Gynecol Oncol, 96(3): 854-6. [Abstract] [Full-text]
32. Combination chemotherapy of docetaxel and carboplatin in advanced or recurrent cervix cancer. A pilot study.
    Gynecol Oncol, 96(3): 805-9. [Abstract] [Full-text]
33. Tailoring the parametrectomy in stages IA2-IB1 cervical carcinoma: is it feasible and safe?
    Gynecol Oncol, 96(3): 792-8. [Abstract] [Full-text]
34. Laser CO2 conization in postmenopausal age: risk of cervical stenosis and unsatisfactory follow-up.
    Gynecol Oncol, 96(3): 771-5. [Abstract] [Full-text]
35. Potential application of the ATP cell viability assay in the measurement of intrinsic radiosensitivity in cervical cancer.
    Gynecol Oncol, 96(3): 765-70. [Abstract] [Full-text]
36. Protective role of the polymorphism CCR2-64I in the progression from squamous intraepithelial lesions to invasive cervical carcinoma.
    Gynecol Oncol, 96(3): 760-4. [Abstract] [Full-text]
37. Glutathione-S-transferase and p53 polymorphisms in cervical carcinogenesis.
    Gynecol Oncol, 96(3): 736-40. [Abstract] [Full-text]
38. Rethinking the use of radiation and chemotherapy after radical hysterectomy: a clinical-pathologic analysis of a Gynecologic Oncology Group/Southwest Oncology Group/Radiation Therapy Oncology Group trial.
    Gynecol Oncol, 96(3): 721-8. [Abstract] [Full-text]
39. Human papillomavirus testing for primary screening in women at low risk of developing cervical cancer. The Greek experience.
    Gynecol Oncol, 96(3): 714-20. [Abstract] [Full-text]
40. Death receptors and ligands in cervical carcinogenesis: an immunohistochemical study.
    Gynecol Oncol, 96(3): 705-13. [Abstract] [Full-text]
41. Human papillomavirus type 16 E2 and E6/E7 variants.
    Gynecol Oncol, 96(3): 695-700. [Abstract] [Full-text]
42. Concurrent chemoradiotherapy using high-dose-rate intracavitary brachytherapy for uterine cervical cancer.
    Gynecol Oncol, 96(3): 665-70. [Abstract] [Full-text]
43. Evaluation of patients after extraperitoneal lymph node dissection for cervical cancer.
    Gynecol Oncol, 96(3): 658-64. [Abstract] [Full-text]
44. New approaches to pathogenic gene function discovery with human squamous cell cervical carcinoma by gene ontology.
    Gynecol Oncol, 96(3): 621-9. [Abstract] [Full-text]
45. Management and clinical outcomes of pregnant patients with invasive cervical cancer.
    Ann Oncol, 16(3): 397-402. [Abstract] [Full-text]
46. Detection and genotyping of human papillomavirus in cervical samples from Italian patients.
    J Med Virol, 75(4): 588-92. [Abstract] [Full-text]
47. The role of amifostine in the treatment of carcinoma of the uterine cervix: an update of RTOG-0116 and review of future directions.
    Semin Oncol, 31(6): 37-41. [Abstract] [Full-text]
48. Hypoxia correlates with angiogenesis in cervical cancers.
    Int J Clin Oncol, 10(1): 35-9. [Abstract] [Full-text]
49. Up-regulation of vascular endothelial growth factor-C by nicotine in cervical cancer cell lines.
    Am J Reprod Immunol, 53(3): 153-8. [Abstract] [Full-text]
50. Naturally processed and HLA-B8-presented HPV16 E7 epitope recognized by T cells from patients with cervical cancer.
    Int J Cancer, 114(5): 766-78. [Abstract] [Full-text]
51. A population-based cohort study of KIR genes and genotypes in relation to cervical intraepithelial neoplasia.
    Tissue Antigens, 65(3): 252-9. [Abstract] [Full-text]
52. Demographic variables routinely collected at colposcopic examination do not predict who will default from conservative management of cervical intraepithelial neoplasia I.
    Aust N Z J Obstet Gynaecol, 45(1): 48-51. [Abstract] [Full-text]
53. Preoperative serum squamous cell carcinoma antigen levels in clinical decision making for patients with early-stage cervical cancer.
    J Clin Oncol, 23(7): 1455-62. [Abstract] [Full-text]
54. Genomic organization of amplified MYC genes suggests distinct mechanisms of amplification in tumorigenesis.
    Cancer Res, 65(4): 1174-9. [Abstract] [Full-text]
55. Comparison of human papillomavirus messenger RNA and DNA detection: a cross-sectional study of 4,136 women >30 years of age with a 2-year follow-up of high-grade squamous intraepithelial lesion.
    Cancer Epidemiol Biomarkers Prev, 14(2): 367-72. [Abstract] [Full-text]
56. The relative distribution of oncogenic types of human papillomavirus in benign, pre-malignant and malignant cervical biopsies. A study with human papillomavirus deoxyribonucleic acid sequence analysis.
    Cancer Detect Prev, 29(1): 37-41. [Abstract] [Full-text]
57. Why do women still develop cancer of the cervix despite the existence of a national screening programme?
    Eur J Obstet Gynecol Reprod Biol, 119(1): 123-4. [Abstract] [Full-text]

© 2004-2008 Cervical Cancer Research Today. All Rights Reserved.